Yes, this is the chief weakness for EOLS with this data. Over/under that they change this when they start being impeded by Daxxy? (Reasonable chance their Q1/Q4 neuromod revenues are better than RVNC’s ratio of same, if so this isn’t an issue for EOLS. Yet)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.